Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
This article was originally published in RPM Report
Executive Summary
The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.
You may also be interested in...
The Slow Death of a Blockbuster
Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA
The relabeling of Aransep and Procrit to address safety issues is taking longer than expected. There's nothing new about that. What is new is how FDA weighed in on the Congressional debate over coverage for the anemia therapies-and how the last step of the regulatory process is likely to play out.